Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

Pachyonychia Congenita: full-pipeline trial registry

2 of 5 indexed Pachyonychia Congenita trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Pachyonychia Congenita: 5 US clinical trials tracked, 2 recruiting.

Pachyonychia Congenita is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Palvella Therapeutics, running 3 of these trials.

Enrollment posture brief

Registry condition pachyonychia-congenita

OPEN 2 | RECR 40% | LATE 2 | EARLY 2 | RANK #3391 | SPON 3

Volume-matched condition peers

Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Pachyonychia Congenita (this)40%
Open-enrollment share among volume-matched conditions near Pachyonychia Congenita

Pachyonychia Congenita lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Pachyonychia Congenita on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Pachyonychia Congenita is recruiting below its size-band peers.

    2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Pachyonychia Congenita research.

    Palvella Therapeutics accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.

  3. Most Pachyonychia Congenita trials plan to enrol fewer than 100 people.

    Median target enrolment is 45 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Pachyonychia Congenita research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 21Phase 32

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 1
Phase 3 2

Top Sponsors

Palvella Therapeutics 3 trials
TransDerm 1 trials
Pachyonychia Congenita Project 1 trials

Named interventions

Most-linked intervention names on Pachyonychia Congenita records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

PTX-022 Drug
3 trials
1% sirolimus cream (TD201 1%) Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Pachyonychia Congenita trials. A trial with sites in several states counts in each.

Utah 3 trials
Minnesota 3 trials
California 3 trials
Arizona 2 trials
Pennsylvania 1 trials
Oregon 1 trials
Illinois 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Pachyonychia Congenita page

5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Pachyonychia Congenita condition card totals 5 registered trials; most-linked intervention PTX-022; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.